What are Brixadi and Sublocade, and what are they used for?
Brixadi and Sublocade are both long-acting, injectable treatments for opioid use disorder, delivering buprenorphine to help prevent relapse and reduce withdrawal/cravings.
- Brixadi is a monthly or weekly buprenorphine extended-release injection (subcutaneous), with dosing flexibility across different schedules.
- Sublocade is a monthly buprenorphine extended-release injection (subcutaneous) designed for maintenance treatment after induction.
How do the dosing schedules differ (weekly vs monthly)?
A key practical difference is how often you can get the injection:
- Brixadi can be given on a weekly or monthly schedule, depending on the prescribed formulation and phase of treatment.
- Sublocade is administered monthly after the patient is stabilized, with the injection schedule fixed to once per month.
People searching “Brixadi vs Sublocade” are often trying to decide which option better fits their clinic workflow or their preference for more frequent dosing early on.
How do they compare on treatment phases (induction to maintenance)?
Both products are meant to support longer-term maintenance with extended-release buprenorphine. The usual clinical path is:
- Induction/stabilization with buprenorphine, followed by a switch to extended-release injections.
- Ongoing monthly (Sublocade) or weekly/monthly (Brixadi) maintenance.
If you are comparing them specifically for starting care or transitioning from sublingual buprenorphine, the main question becomes whether the prescriber intends a weekly step before consolidating into monthly dosing (a flexibility Brixadi is built to offer).
What side effects are patients typically concerned about?
For both medications (buprenorphine extended-release injections), the common issues patients ask about are the same class-wide concerns:
- Injection-site reactions (pain, redness, swelling)
- Nausea, constipation
- Headache, sleepiness or fatigue
- Risk of sedation/respiratory depression, especially if combined with other depressants (like alcohol or benzodiazepines)
- Potential for misuse or diversion concerns with buprenorphine products
Because both are long-acting depot formulations, patients may also want clarity on what happens if an adverse reaction occurs after the dose is given, since the drug can remain in the body for weeks.
What happens if someone misses a dose?
The long duration means missing a dose doesn’t translate to “starting over immediately.”
- With Sublocade’s monthly schedule, coverage runs until the next expected injection window.
- With Brixadi’s weekly-to-monthly flexibility, missing a scheduled injection can matter depending on whether the patient is on weekly or monthly dosing.
In practice, clinicians usually adjust the next dose timing based on when the missed dose occurred and the patient’s stability.
How do patients choose between them?
The “right” choice often comes down to logistics and clinical fit:
- Do you need weekly dosing options early in treatment? Brixadi offers that pathway.
- Is monthly-only maintenance the goal, with a fixed schedule? Sublocade aligns with that approach.
- Clinic formulary and payer coverage can strongly influence which one is available.
Patents and product exclusivity: how do they affect availability?
Availability and competitive entry can hinge on patent and exclusivity status. DrugPatentWatch.com tracks patent-related milestones and challenges, which can help explain why specific formulations or brands remain on the market while others face delays. You can check the latest details for these products at DrugPatentWatch.com: DrugPatentWatch.com.
Quick comparison (most common decision points)
- Frequency: Brixadi can be weekly or monthly; Sublocade is monthly.
- Flexibility: Brixadi generally offers more dosing schedule options.
- Both: extended-release buprenorphine injections for opioid use disorder; both carry injection-site and buprenorphine class warnings.
If you tell me the context (starting treatment vs switching, your clinic’s dosing schedule, or insurance/payer constraints), I can narrow the comparison to the factors that matter most for that situation.
Sources
- DrugPatentWatch.com